Youcef M. Rustum

Youcef M. Rustum's AcademicInfluence.com Rankings

Youcef M. Rustum

Medical

#2571

World Rank

#3000

Historical Rank

Oncology

#162

World Rank

#168

Historical Rank

Pharmacology

#269

World Rank

#317

Historical Rank

medical Degrees

Youcef M. Rustum

Philosophy

#7408

World Rank

#10618

Historical Rank

Logic

#4459

World Rank

#5754

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Youcef M. Rustum Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Youcef M. Rustum's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. (1987) (417)
Irinotecan in the treatment of colorectal cancer: clinical overview. (2001) (302)
P-glycoprotein in human sarcoma: evidence for multidrug resistance. (1987) (266)
Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. (1990) (238)
Potential regional differences for the tolerability profiles of fluoropyrimidines. (2008) (225)
Flow cytometric analysis of DNA aneuploidy in primary and metastatic human solid tumors. (1984) (214)
Selective Modulation of the Therapeutic Efficacy of Anticancer Drugs by Selenium Containing Compounds against Human Tumor Xenografts (2004) (212)
Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy. (1979) (212)
A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. (1982) (200)
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. (1997) (192)
Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. (2002) (182)
Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. (1982) (179)
Isolation and characterization of renin-expressing cell lines from transgenic mice containing a renin-promoter viral oncogene fusion construct. (1990) (167)
Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. (1979) (160)
Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. (1984) (159)
High-pressure liquid chromatography. I. Quantitative separation of purine and pyrimidine nucleosides and bases. (1978) (141)
Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. (1992) (133)
Relationship between DNA ploidy, glandular differentiation, and tumor spread in human prostate cancer. (1985) (131)
Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. (1982) (125)
5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. (1994) (125)
MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. (1996) (117)
Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. (1998) (112)
Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. (1992) (106)
MicroRNA-627 mediates the epigenetic mechanisms of vitamin D to suppress proliferation of human colorectal cancer cells and growth of xenograft tumors in mice. (2013) (106)
Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. (2000) (104)
Characterization of cells obtained by mechanical and enzymatic means from human melanoma, sarcoma, and lung tumors. (1981) (103)
A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity (2012) (99)
Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. (1990) (97)
Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. (1998) (96)
Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts (2004) (96)
Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. (1987) (93)
Chromosomes and causation of human cancer and leukemia. XLIV. A method for chromosome analysis of solid tumors. (1981) (92)
Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles. (1976) (88)
Methylseleninic Acid Potentiates Apoptosis Induced by Chemotherapeutic Drugs in Androgen-Independent Prostate Cancer Cells (2005) (87)
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. (1999) (87)
Yeast Hexokinase. I. Preparation of the Pure Enzyme (1966) (82)
Tumor Vascular Maturation and Improved Drug Delivery Induced by Methylselenocysteine Leads to Therapeutic Synergy with Anticancer Drugs (2008) (80)
Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. (1987) (79)
1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. (1992) (77)
Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. (1987) (75)
USE OF LIPOSOMES FOR THE ENHANCEMENT OF THE CYTOTOXIC EFFECTS OF CYTOSINE ARABINOSIDE * (1978) (75)
DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. (1996) (74)
Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) (1997) (73)
Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia. (1979) (70)
Proliferative characteristics of primary and metastatic human solid tumors by DNA flow cytometry. (1984) (70)
Growth of cell colonies in soft agar from biopsies of different human solid tumors. (1980) (69)
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α (2010) (67)
Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size. (1979) (67)
Metabolism and intracellular retention of 1-beta-D-arabinofuranosylcytosine as predictors of response of animal tumors. (1978) (67)
Reversible depression of the reticuloendothelial system by liposomes. (1982) (66)
Inhibition of liver metastases of M 5076 tumor by liposome-entrapped adriamycin. (1983) (65)
Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes. (1979) (65)
Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. (1995) (65)
Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models (2014) (64)
Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. (1988) (64)
A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer (2009) (64)
Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. (1998) (63)
Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison (2005) (62)
Colony growth in soft agar of human melanoma, sarcoma, and lung carcinoma cells disaggregated by mechanical and enzymatic methods. (1980) (60)
A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma. (1987) (60)
DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. (1996) (60)
Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats. (1983) (59)
d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. (1996) (58)
Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. (1995) (57)
Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. (1998) (56)
Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. (2005) (56)
Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. (1989) (55)
Prognostic Applications of DNA Flow Cytometry for Human Solid Tumors a (1986) (55)
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. (2003) (55)
Effect of thymidine on the toxicity, antitumor activity, and metabolism of 1-beta-D-arabinofuranosylcytosine in rats bearing a chemically induced colon carcinoma. (1980) (53)
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition (2012) (53)
Lack of Microvessels in Well-Differentiated Regions of Human Head and Neck Squamous Cell Carcinoma A253 Associated with Functional Magnetic Resonance Imaging Detectable Hypoxia, Limited Drug Delivery, and Resistance to Irinotecan Therapy (2004) (52)
Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. (1996) (52)
New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. (1994) (51)
Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia. (1985) (50)
Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin. (2002) (48)
Dissociation of yeast hexokinase under the influence of substrates. (1972) (48)
Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration. (1992) (47)
5-Ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil (1994) (47)
High correlation of whole-body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer. (2005) (47)
Thymidylate synthase: a critical target in cancer therapy? (2004) (46)
Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. (1998) (46)
Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. (2000) (46)
Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers (2010) (45)
PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. (1996) (44)
Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma. (1996) (42)
Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line. (1995) (41)
Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis. (1998) (40)
Mechanisms of resistance to fluoropyrimidines. (1992) (40)
Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. (2008) (39)
Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation. (1998) (38)
Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor. (1992) (37)
Effects of diastereoisomers of 5-formyltetrahydrofolate on cellular growth, sensitivity to 5-fluoro-2'-deoxyuridine, and methylenetetrahydrofolate polyglutamate levels in HCT-8 cells. (1991) (37)
Biochemical characteristics, metabolism, and antitumor activity of several acetylated hexosamines. (1977) (36)
Yeast Hexokinase. IV. Multiple forms of hexokinase in the yeast cell. (1971) (36)
Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. (1997) (35)
Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. (2006) (35)
A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors (2008) (35)
Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: relevance to cell growth inhibition. (1991) (35)
Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model. (1996) (34)
A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. (2006) (34)
Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1 (2011) (34)
Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor. (2009) (33)
Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer. (2011) (33)
Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells (1997) (33)
Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C. (1987) (32)
Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex. (1999) (32)
A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. (2006) (32)
Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil (2007) (31)
Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance. (1998) (30)
Toxicity and antitumor activity of 5‐fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin (1989) (30)
Genetic analysis of liver tumorigenesis in SV40 T antigen transgenic mice implies a role for imprinted genes. (1994) (30)
Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines. (1993) (30)
5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. (1995) (28)
Cell cycle: Molecular targets for diagnosis and therapy: Tumor suppressor genes and cell cycle progression in cancer (1998) (27)
Contrasting patterns of DNA fragmentation induced by thymidylate synthase inhibitors, ZD1694 and AG-331. (1995) (27)
Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C). (1985) (27)
Synergistic antitumor activity of capecitabine in combination with irinotecan. (2005) (27)
Treatment of advanced-stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: a pilot study. (1988) (27)
Phase I and pharmacologic studies of intraperitoneal leucovorin and 5-fluorouracil in patients with advanced cancer. (1986) (26)
Separation of leukemic cells into proliferative and quiescent subpopulations by centrifugal elutriation. (1977) (26)
Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. (1997) (26)
Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment. (1982) (26)
Changes in ribo- and deoxyribonucleoside triphosphate pools within the cell cycle of a synchronized mouse fibroblast cell line. (1983) (26)
Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. (2000) (26)
Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas (1996) (25)
Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer (2000) (25)
Roswell Park Cancer Institute (2020) (25)
Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development (2018) (25)
Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines (1999) (25)
The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells (2006) (24)
Inability of liposome encapsulated 1-beta-D-arabinofuranosylcytosine nucleotides to overcome drug resistance in L1210 cells. (1981) (24)
The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma. (1988) (24)
Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. (1999) (23)
Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells (2000) (23)
Methods for the separation and identification of ribonucleotides on DEAE-cellulose. (1973) (23)
Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine. (1999) (23)
Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: survivin expression overlaps with stem cell markers. (2010) (23)
Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. (2007) (23)
Growth of human urological tumors on extracellular matrix as a model for the in vitro cultivation of primary human tumor explants. (1986) (23)
Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350. (2002) (23)
Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine. (1994) (22)
Modulation of fluoropyrimidines by leucovorin: Rational and status (1991) (22)
5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. (1995) (22)
Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts. (2011) (22)
Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin. (1998) (22)
Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment (2018) (22)
Mechanisms of the in vivo resistance to adriamycin and modulation by calcium channel blockers in mice. (1989) (21)
Serial cytogenetic analysis of a recurrent malignant melanoma. (1984) (21)
Extended phase I study of capecitabine and weekly irinotecan as first-line chemotherapy in metastatic colorectal cancer (2001) (20)
α-Fluoro-β-alanine: Effects on the antitumor activity and toxicity of 5-fluorouracil (2000) (20)
Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts. (2008) (19)
New drugs in therapy of colorectal cancer: preclinical studies. (1999) (19)
Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26. (1993) (18)
Cellular heterogeneity in DNA damage and growth inhibition induced by ICI D1694, thymidylate synthase inhibitor, using single cell assays. (1994) (18)
Recent advances in the study of rTS proteins. rTS expression during growth and in response to thymidylate synthase inhibitors in human tumor cells. (1997) (18)
Assessment of human genitourinary tumors and chemosensitivity testing in 3-dimensional collagen gel culture. (1990) (18)
Novel approaches to selective treatments of human solid tumors: laboratory and clinical correlation. (1993) (17)
Differential selectivity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in cultured human B lymphocytes and mouse L1210 leukemia. (1983) (17)
The preparation of yeast hexokinases. (1971) (17)
Generation and characterization of a low-degree drug-resistant human tumor cell line. (1990) (17)
Comparison of an immunoperoxidase "sandwich" staining method and western blot detection of P-glycoprotein in human cell lines and sarcomas. (1992) (17)
1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response. (1985) (16)
In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933. (1993) (16)
Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression. (2004) (16)
Targeting the Nrf2-Prx1 Pathway with Selenium to Enhance the Efficacy and Selectivity of Cancer Therapy (2007) (16)
Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells. (1999) (16)
Downregulation of Cystine Transporter xc– by Irinotecan in Human Head and Neck Cancer FaDu Xenografts (2010) (16)
The use of liposomes as carriers of therapeutic agents. (1985) (16)
Modulation of 1-beta-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia. (1985) (16)
Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck. (2015) (16)
p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex). (1997) (15)
Fluoropyrimidines in Cancer Therapy (2002) (15)
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma—Bench-to-Bedside Therapy (2018) (15)
Extrachromosomal chromatin: novel target for bleomycin cleavage in cells and solid tumors. (1991) (15)
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors (2005) (15)
Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues. (1982) (15)
Pharmacologic rationale for fluoropyrimidine-leucovorin combination: biochemical mechanisms. (1992) (15)
The determination of growth rates of individual colonies in agarose using high-resolution automated image analysis. (1990) (14)
Isolation and characterization of a human ileocecal carcinoma cell line (HCT-8) subclone resistant to fluorodeoxyuridine. (1993) (14)
Bioavailability of high-dose oral leucovorin. (1987) (14)
Architectural Heterogeneity in Tumors Caused by Differentiation Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound (2010) (14)
Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP. (1989) (14)
Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells. (1992) (13)
Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resist (1999) (13)
Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications. (1999) (13)
In vivo toxicity evaluation of gold-dendrimer composite nanodevices with different surface charges (2013) (13)
Comparison of the membrane-related effects of cytarabine and other agents on model membranes. (1985) (13)
Reversed-phase ion-pair high-performance liquid chromatographic assay of 5-fluorouracil, 5'-deoxy-5-fluorouridine, their nucleosides, mono-, di-, and triphosphate nucleotides with a mixture of quaternary ammonium ions. (1982) (13)
Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer. (2015) (12)
Potential Role of Selenium in the Treatment of Cancer and Viral Infections (2022) (12)
Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036. (1989) (12)
Multifactorial cellular determinants of the action of antimetabolites. (1976) (12)
A phase II trial of 5‐fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinoma (1990) (12)
The treatment of patients with acute nonlymphocytic leukemia in remission. (1985) (12)
Therapeutic Efficacy of Cytosine Arabinoside Trapped in Liposomes (1982) (12)
Targeting Molecular Signals in Chk1 Pathways as a New Approach for Overcoming Drug Resistance (2004) (12)
A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance (1996) (12)
The role of drug sequence in therapeutic selectivity of the combination of 5-fluorouracil and cis-platin. (1989) (12)
Does celecoxib have a role in the treatment of patients with colorectal cancer? (2009) (11)
The soft agar clonogenicity and characterization of cells obtained from human solid tumors by mechanical and enzymatic means (2004) (11)
Clinical implications of 5-FU modulation. (1999) (11)
An enzymatic method for the disaggregation of human solid tumors for studies of clonogenicity and biochemical determinants of drug action. (1980) (11)
S-phase modulation by irinotecan: pilot studies in advanced solid tumors (2005) (11)
The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer (2001) (11)
Metabolic Modulation and Cellular de novo versus Salvage Metabolism1 (1980) (11)
Investigation of hydrophobically derivatized hyperbranched polyglycerol with PEGylated shell as a nanocarrier for systemic delivery of chemotherapeutics. (2015) (11)
Modulation of doxorubicin-induced DNA lesions by verapamil, DMDP and dipyridamole in resistant P388 cell lines. (1990) (10)
Constitutive Expression of HIF-&agr; Plays a Major Role in Generation of Clear-cell Phenotype in Human Primary and Metastatic Renal Carcinoma (2014) (10)
Rational basis for the metabolic modulation of 5‐fluorouracil by leucovorin and interferon alpha (1991) (10)
Double Immunohistochemical Staining Method for HIF-1α and its Regulators PHD2 and PHD3 in Formalin-fixed Paraffin-embedded Tissues (2010) (10)
Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid. (1990) (10)
Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation. (2011) (10)
Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells (2008) (9)
Resistance to cytosine arabinoside in cells transfected with activated Ha-ras oncogene. (1995) (9)
Preclinical Development of Eniluracil: Enhancing the Therapeutic Index and Dosing Convenience of 5-Fluorouracil (2000) (9)
Down-regulation of c-myc gene expression with induction of high molecular weight DNA fragments by fluorodeoxyuridine. (1994) (9)
A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer (2007) (9)
Current status of chemotherapy sensitivity testing for urological malignancies. (1986) (9)
Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine. (1983) (8)
Histopathologic technique for the morphological examination of fixed or frozen solid tumor cells in soft agar. (1981) (8)
Time-lapse video reveals immediate heterogeneity and heritable damage among human ileocecal carcinoma HCT-8 cells treated with raltitrexed (ZD1694). (2000) (8)
Differing effects of inducers of differentiation on the ribonucleotide pool sized of Friend leukemia cells. (1975) (8)
Quantitation of dihydrofolate reductase and thymidylate synthase mRNAs in vivo and in vitro by polymerase chain reaction. (1992) (8)
Metabolism of N6-(Δ2-isopentenyl)adenosine in rat liver (1974) (8)
Novel cellular determinants for reversal of multidrug resistance in cells expressing P170-glycoprotein. (1998) (8)
Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen (2004) (8)
alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil. (2000) (8)
In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer. (1991) (8)
Cellular Heterogeneity of Human Tumors (1985) (8)
Chemotherapeutic efficacy of 5-fluorouracil with concurrent thymidine infusion against transplantable colon tumors in rodents. (1984) (8)
The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and-sensitive leukemia in vitro and in vivo (2004) (8)
Phase1 clinical trial of high doses of Seleno-L-methionine (SLM), in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients. (2018) (8)
Selectivity of action of 5-FU: biochemical basis. (1979) (7)
Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38. (2002) (7)
A method for continuous drug infusion in unrestrained rats: its application in evaluating the toxicity of 5-fluorouracil/thymidine combinations. (1979) (7)
126 Interactions and cross resistance patterns between various schedules of 5-FU and the new, folate-based thymidilate synthase inhibitor tomudex (D1694) (1995) (7)
Role of administration route in the therapeutic efficacy of doxifluridine. (1987) (7)
The design of cancer chemotherapy: metabolic modulation and cellular de novo versus salvage metabolism. (1980) (7)
Determinants of response to antimetabolites and their modulation by normal purine and pyrimidine metabolites. (1981) (7)
Growth of human urologic tumors on extracellular matrix. (1986) (7)
Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience. (1990) (6)
A phase I-II study on the toxicity and therapeutic efficacy of 5-fluorouracil in combination with leucovorin and cisplatinum in patients with advanced colorectal carcinoma. (1990) (6)
Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines. (1997) (6)
Studies on the selective toxicity of guanazole in mice. (1978) (6)
Progress report on studies of FAM-CF for gastric cancer and intraperitoneal administration of FUra-CF followed by cisplatin (DDP). (1988) (6)
Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. (1997) (6)
Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment. (1985) (6)
Preliminary results of phase I clinical trial of high doses of seleno-L-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients. (2019) (5)
Tissue-specific effects of N 6 -( 2 -isopentenyl) adenosine on the incorporation of precursors into nucleic acids and protein in rats and mice. (1972) (5)
Fluorouracil and leucovorin: there is a choice. (1993) (5)
Mechanisms of acquired resistance to modulation of 5-fluorouracil by leucovorin in HCT-8 human ileocecal carcinoma cells. (1997) (5)
Correlation of tumor-cell growth in four semisolid systems (2004) (5)
The emerging role for biomodulation of antineoplastic agents. (1992) (5)
Topoisomerase II-mediated DNA damage of episomes in tumor-bearing mice. (1990) (5)
Randomized Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck (2013) (5)
Limitations of Drug Sensitivity Testing in Soft Agar for Clinical Management of Patients With Ovarian Carcinoma (1985) (5)
Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays. (1993) (5)
Friend leukemia cells: relationship between differentiation, clonogenicity and malignancy. (1978) (5)
Cisplatinum in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma. (1992) (5)
Drug Uptake and Ribonucleotide Profiles of Blast‐enriched and Blast‐depleted Human Bone Marrow Cell Populations (1977) (5)
Biochemical and Clinical Studies of (1978) (5)
Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity (2012) (4)
Prediction of therapeutic response in acute myelocytic leukemia. (1979) (4)
Growth slow‐down and growth arrest of human colon carcinoma cells HCT‐8 in vitro after exposure to 5‐fluoro‐2′‐deoxyuridine (1993) (4)
Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity. (1996) (4)
A phase I and biological correlates study of capecitabine (CAP) + oxaliplatin (OX) + radiation therapy (RT) in locally advanced rectal cancer (LARC) (2005) (4)
Expression of the MRP and MDRI Multidrug Resistance Gene Products in 160 Untreated Human Carcinomas Studied by Immunohistochemical Methods in Formalin-Paraffin Sections (1998) (4)
Roleof LiposomeType and Routeof Administrationin the Antitumor Activityof Liposome-entrapped I -fJ-D-arabinofuranosylcytosine againstMouse L1210Leukemia1 (1979) (4)
Model of Pancreatic Cancer Imaging and Magnetic Resonance Imaging on an Orthotopic High Correlation of Whole-Body Red Fluorescent Protein (2005) (4)
Selective modulation of 5-fluorouracil action in patients with colorectal carcinoma. (1985) (4)
Schedule-dependent efficacy of idarubicin (Ida) and doxorubicin (Dox). (1994) (4)
Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside (2004) (4)
Approaches to overcome in vivo anti-cancer drug resistance. (1986) (4)
A phase I and pharmacokinetic (PK) study of high dose selenomethionine (SLM) in combination with irinotecan (IRI) in patients with advanced solid tumors (2005) (3)
Image analysis for quantitation of solid tumor drug sensitivity. (1999) (3)
Biological activities of 5-fluorouracil and its prodrug 5'-deoxy-5-fluorouridine in rats. (1987) (3)
A model for mimicking the pharmacokinetics of chemotherapy drugs for evaluation of drug effects in a soft agar colony formation assay system. (1991) (3)
The combined-action of ici-d1694, 5-fluoro-2'-deoxyuridine and 5-Fluorouracil in inhibiting the growth of a human renal-cell carcinoma cell-line (rpmi-se) in-vitro. (1994) (3)
Correspondence re: W. R. Greco et al., Application of a New Approach for the Quantitation of Drug Synergism to the Combination of cis-Diamminedichloroplatinum and 1-β-d-Arabinofuranosylcytosine. Cancer Res., 50: 5318–5327, 1990.—Reply (1992) (3)
Procurement of Proliferative and Quiescent Acute Leukemia Cells by Centrifugal Elutriation (1978) (3)
Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma (2004) (3)
The effects of verapamil and a tiapamil analogue , DMDP , on adriamycin-induced cytotoxicity in P 388 adriamycin-resistant and-sensitive leukemia in vitro and in vivo (3)
A CRITICAL TARGET IN CANCER THERAPY ? (2004) (3)
Effects of cytosine arabinoside on unseparated bone marrow and peripheral blood cells and on specimens enriched for myeloblasts and promyelocytes. (1980) (3)
Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system. (1993) (3)
Biochemical and clinical studies of chronic lymphocytic leukemia. (1978) (3)
Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells. (2003) (3)
Cellular Topoisomerase I Inhibition and Antiproliferative Activity (2004) (3)
Modulation of the antitumor-activity of 5-Fluorouracil and cisplatinum by N-phosphonacetyl-L-aspartate in the murine colon-carcinoma number-26. (1994) (2)
Comparison of 5-fluoro-2'-deoxyuridine and 5-fluorouracil in the treatment of murine colon cancer; effects on thymidylate synthase. (1994) (2)
Yeast hexokinase. V. Subunit structure and hybridization of isoenzymes. (1971) (2)
Glucose consumption end point in primary histoculture indicates recovery of human tumors from drug treatment (1992) (2)
[Therapy of acute nonlymphocytic leukemia: 2. Biological characteristics and prediction of response]. (1979) (2)
Levels of circulating endothelial cells (CECs) as early pharmacodynamic markers of activity of anti-angiogenic (AA) therapy in advanced pancreatic cancer (PC). (2006) (2)
Computerized image-analysis quantitation of heterogeneity of response in k562 human leukemia-cells after methotrexate exposure. (1993) (2)
A phase I dose escalation study of selenomethionine (SLM) in combination with fixed dose irinotecan (Iri) in patients with solid tumors (2007) (2)
Biologic modulation of 5-fluorouracil with high-dose leucovorin and combination chemotherapy of 5-fluorouracil and cisplatin in metastatic colorectal adenocarcinoma. (1987) (2)
Efficacy of liposome-entrapped cyrtosine arabinoside (ara-c) compared with infused "free" ara-c against l1210 tumor. Abstr. (1980) (2)
Cytotoxicity dna cross links strand breaks and dna repair induced by a new nitrosourea s 10036 (1988) (2)
A combination of 5-fluorouracil and thymidine in advanced colorectal carcinoma (2004) (2)
Synergistic effect of selenium compounds with radiation therapy in human A549 lung xenografts (2007) (2)
Inhibitionof Tumor Cell Growthin Vitro and in Vivoby 1-@3.D- Arabinofuranosylcytosine EntrappedwithinPhospholipidVesicles1 (1976) (2)
Concurrent Carboplatin, Paclitaxel, and Selenomethionine in Combination With Radiation for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase 2 Multicenter Trial (2013) (2)
5-Fluorouracil Prodrug, Ftorafur, Modulated by Uracil (UFT): Preclinical and Clinical Prospective (1997) (2)
A phase II trial of 5-fluorouracil and high-dose leucovorin in gastric carcinoma and a phase I trial of intraperitoneal 5-fluorouracil and leucovorin. (1987) (2)
A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma. (1991) (2)
Se-(methyl)selenocysteine (MSC) potentiates the antitumor activity of irinotecan against human tumor xenografts and protects against drug induced toxicity. (2004) (2)
Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26. (1995) (2)
Chemotherapeutic strategies for treatment of colorectal cancer: present and future developments. (2001) (2)
Effect of doxorubicin, daunorubicin, and idarubicin on the growth rate of human leukemia cells (K562) studied with image analysis. (1993) (2)
Role of cholesterol in enhancing the antitumor activity of 1-beta-d arabinofuranosylcytosine (ara-c) entrapped in reverse phase evaporation vesicles (rev). Abstr. (1979) (2)
5-Fluorouracil Plus Thymidine or Leucovorin by Continuous I.V. Infusion in the Treatment of Advanced Colorectal Carcinoma (1986) (1)
Effects of liposome entrapped adriamycin (am) against ovarian tumor m5076 "metastatic" to the liver. Abstr. (1981) (1)
PD39-02 RESULTS OF PHASE 1 CLINICAL TRIAL OF HIGH DOSES OF SELENO-L-METHIONINE (SLM) IN SEQUENTIAL COMBINATION WITH AXITINIB IN PREVIOUSLY TREATED AND RELAPSED CLEAR CELL RENAL CARCINOMA (CCRCC) PATIENTS (2020) (1)
Selective cytotoxicity and metabolism of beta-d-4'-hydroxy-ftorafur (oh-ft) and 5'-deoxy-5-fluorouridine (dfur). Abstr. (1981) (1)
Selenium Potentiates the Antitumor Activity of Radiation Therapy in Human A549 Lung Cancer Xenografts (2007) (1)
Design of adjuvant chemotherapy based on target cell determinants of drug action: possibilities and limitations. (1979) (1)
Correlationbetween LeukemicCell Retentionof 1-@3-D- Arabinofuranosylcytosine 5'-Triphosphateand Responseto Therapy1 (1979) (1)
Modulation of target enzyme associated with the action of antifolates. (1994) (1)
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition (2012) (1)
Selenium Enhances the Anti-Angiogenic Effects of Bevacuzimab (Anti-VEGF Antibody) in Human Acute Myeloid Leukemia Xenograft Models. (2007) (1)
Reversal of P-glycoprotein (P-gp) and non-P-gp related multidrug resistance (MDR) in vitro and in vivo by RO44–5912 and PAK104p correlated with drug retention and DNA repair: 59 (1994) (1)
Se-(methyl)selenocysteine (MSC) potentiates the antitumor activity of irinotecan against human tumor xenografts and protects against drug induced toxicity (2004) (1)
p 53 and WAF 1 Are Induced and Rb Protein Is Hypophosphorylated during Cell Growth Inhibition by the Thymidylate Synthase Inhibitor ZD 1694 ( Tomudex ) (1997) (1)
Technical Advances New Immunohistochemical "Sandwich" Staining Method for mdrl P-Glycoprotein Detection with JSB-1 Monoclonal Antibody in Formalin-Fixed, Paraffin-Embedded Human Tissues (2007) (1)
Biochemical effects of 2'-azido-2'-deoxyarabinofuranosyl cytosine (cytarazid) in leukemia l1210 and hela cells. Abstr. (1980) (1)
Relationship between ribonucleotide profile and reliance of tumor and normal cells on salvage and de novo pathways. Abstr. (1978) (1)
Celecoxib in combination with irinotecan (CPT-11), 5-fluorouracil and leucovorin in patients with advanced cancer: A phase I, pharmacokinetic study (2005) (1)
Effects of DMDP, a tiapamil analogue, on adriamycin efflux in adriamycin-resistant and -sensitive P388 cells. (1987) (1)
613 Plasma and tissue distribution of selenium after 5-methylselenocysteine (MSC) or seleno-L-methionine (SLM) in mice bearing human tumor xenografts (2004) (1)
Phase I with expansion clinical trial of seleno-l-methionine (SLM) in combination with axitinib in patients with relapsed clear cell renal cell carcinoma (ccRCC): Bench to bedside. (2021) (1)
Phase Ml Trial of High-Dose Calcium Leucovorin and 5-Fluorouracil in Advanced Colorectal Cancer1 (2006) (1)
APhase I and Pharmacokinetic Study of Fixed-Dose Selenomethionine and Irinotecan in SolidTumors (2006) (1)
A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patients with colorectal carcinoma (2004) (1)
Organ-specific differences in the metabolism of N6-(Δ2-isopentenyl)-adenosine☆ (1976) (0)
Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in prostate cancer cells through enhancing caspase activation (2005) (0)
Question-and-Answer Session (2007) (0)
Metabolism of N6-(delta 2-isopentenyl)adenosine in rat liver. (1974) (0)
DNA PLOIDY AND TUMOR SPREAD IN HUMAN PROSTATE CANCER Tables Glandular differentiation ( Gleason score ) in 40 prostate carcinomas related to tumor stage Tables Relationship between ONA ploidy (2006) (0)
107 Heterogeneity in DNA-damage in vivo by FdUrd in mice bearing colon carcinoma #26 tumors (1995) (0)
In vivo toxicity study of gold composite nanodevices for use in imaging and radiotherapy (2009) (0)
Determinants of Ara-C action: biochemical consideration. (1983) (0)
399 – MODIFICATION OF TOXICITY AND ANTITUMOR ACTIVITY OF 5-FLUOROURACIL (FU) BY NORMAL METABOLITES IN RATS AND MICE (1978) (0)
Current Landscape and the Potential Role of HIF and Selenium in Clear Cell Renal Cell Carcinoma Treatment (2018) (0)
N6-substituted adenosines. Comparison of their metabolism and anti- tumor activity. Abstr. (1975) (0)
The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy (2012) (0)
Comparative Antitumor Activity of 5-Fluorouracil (5-FU) Prodrugs in Preclinical Model Systems (2003) (0)
The Value of Flow Cytometry on Staging and Survival in Patients with Adenocarcinoma of the Prostate (1987) (0)
Differentiation, clonogenicity and malignancy of friend leukemia cells (flc). Abstr. (1977) (0)
Abstract 4284: Combined magnetic resonance and fluorescence-protein imaging to simultaneously assess the anti-tumor and anti-angiogenesis efficacy of selenium (2011) (0)
Distribution of Irinotecan in Liver and a Human Tumor Xenograft Model by Tissue Imaging Mass Spectrometry (2012) (0)
Role of Dosf, Schedule and Route of Administration of 5-Formyltetra-Hydrofolate: Preclinical and Clinical Investigations (1988) (0)
Enrico Mihich, MD: In Memoriam (1928-2016). (2017) (0)
Role of dose, schedule and route of administration of 5-formyltetra-hydrofolate: preclinical and clinical investigations. (1988) (0)
Carcinomas 5-Fluorouracil and Thymidine in Treatment of Colorectal Clinical Pharmacological Studies of Concurrent Infusion of Updated (2006) (0)
Role of biochemical pharmacology in the design of new clinical combination treatments based on the concept of metabolic modulation (1985) (0)
John McGuire and Youcef Rustum Comment (2000) (0)
CAPECITABIN : EIN ORALES FLUOROPYRIMIDIN (1998) (0)
Notice of Retraction Re : (2006) (0)
Panel Discussion of Future Directions (1988) (0)
Abstracts of Poster Presentations (2004) (0)
New concepts in cancer (1990) (0)
GROUP PHASE III EXPERIENCE WITH THE MODULATION OF 5-FLUOROURACIL BY LEUCOVORIN IN METASTATIC COLOFECTAL ADENOCARCINOMA I (1988) (0)
510 Pharmacokinetics (PK) and effects on irinotecan (CPT-11) disposition of selenium (Se) during a phase I study of CPT-11 in combination with selenomethionine (SLM) in patients with advanced solid tumors (2004) (0)
Comparative Antitumor Activity of 5-Fluorouracil (5-FU) Prodrugs in Preclinical Model Systems: Role of Leucovorin and Dihydropyrimidine Dehydrogenase Inhibitors (2002) (0)
Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy (2023) (0)
Effects of 3-deazauridine (daur) on the metabolism of 5-aza-cytidine (aza-cr) by l1210 cells resistant to arabinosyl-cytosine (l1210/ara-c) and sensitive cells. Abstr. (1981) (0)
1-ÃŸ-o-Arabinof uranosy Icytosine Metabolism and Incorporation into DMA as Determinants of in Vivo Murine Tumor Cell Response1 (2006) (0)
Contents, Vol. 47, 1990 (1990) (0)
The role of target determinants in antineoplastic therapy. (1981) (0)
Methylseleninic Acid (MSA) Decreases DNA Synthesis, Induces Cell Death, and Sensitizes Both Rituximab Sensitive and Rituximab-Resistant Non-Hodgkin’s Lymphoma Cell Lines to the Anti-Tumor Activity of Cisplatin and Gemcitabine. (2007) (0)
Metabolic Modulation of Ara-C (1986) (0)
Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance (1991) (0)
Relationship between DMA Ploidy, Glandular Differentiation, and Tumor Spread in Human Prostate Cancer1 (2006) (0)
Human Solid Tumors Growth of Cell Colonies in Soft Agar from Biopsies of Different Updated (2006) (0)
Antitumor Activity of ZD 1694 ( Tomudex ) against Human Head and Neck Cancer in Nude Mouse Models : Role of Dosing Schedule and Plasma Thymidine 1 (1999) (0)
Abstract LB-160: Dual application of TLR5 agonist in cancer treatment: A single agent combines supporting care and antitumor activities (2011) (0)
The effect of selenium on the oncogenic protein {beta}-catenin in human colorectal cancers. (2010) (0)
Enhancing efficacy of the multi-drug resistance-sensitive compound T138067 by advance treatment with negative modulators of the inhibitor of apoptosis protein survivin (2007) (0)
Mice Bearing Advanced Colon Carcinoma 26 -deoxyuridine ± N-Phosphonacetyl-l-aspartate in ' 5-Fluoro-2Activity of the Weekly Intravenous Push Schedule of (2013) (0)
Synergistic interaction between 3-deazauridine (daur) and arabinosylcytosine (ara-c) in mice bearing l1210. Abstr. (1980) (0)
Sex differences in pharmacokinetics and antitumor activity of 3-deazauridine (daur) in mice. Abstr. (1978) (0)
Modulation of 1-ÃŸ-D-Arabinofuranosy Icytosine Metabolism by Thymidine in Human Acute Leukemia1 (2006) (0)
Organ-specific differences in the metabolism of N6-(delta2-isopentenyl)-adenosine. (1976) (0)
Role of Inducible Nitric Oxide Synthase (iNOS) in Regulation of Nitric Oxide (NO) Production and Stabilization of HIF-1α: Potential Role of Se-Methylselenocysteine (MSC), an Antioxidant Multi-targeted Small Molecule (2010) (0)
Modulation of survivin expression: A potential therapeutic drug action mechanism for drug resistance and drug sensitivity (2005) (0)
Differential sensitivity of mouse tumors to arabinosyl cytosine (ara-c) in vivo. Abstr. (1977) (0)
Response and toxicity of ten days continuous infusion of 5-fluorouracil and intermittent leucovorin in advanced breast cancer (1993) (0)
Contents, Supplement 1, 1997 (1997) (0)
Cytotoxicity dna cross links strand breaks and dna repair induced by the new nitrosourea fotemustine (1988) (0)
Heterogeneity of DNA-damage in ovarian cancer cell lines A2780-WT and multiple drug resistant (mdr) A2780-Dox-5 treated with adriamycin(ADM) (2007) (0)
Bis(guanylhydrazone) (mgbg). Abstr. (1978) (0)
Novel Approaches to Selective Treatments of Human Solid Tumors (2012) (0)
Effects of Tumor Necrosis Factor-related Apoptosis-inducing Ligand Alone and in Combination with Chemotherapeutic Agents on Patients ’ Colon Tumors Grown in SCID Mice 1 (2002) (0)
Comparative antitumor activity and metabolism of 5'-deoxy-5-fjuorouridine (dfur) and 5-fluorouracil (fu) in transplanted tumors in rodents. Abstr. (1983) (0)
Image analysis using the fluorochromasia assay to quantify tumor drug sensitivity. (2005) (0)
Predictive tests for cancer chemotherapy and the problem of tumor cell heterogeneity. (1988) (0)
MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets (2022) (0)
Abstract 3512: Regulation of hypoxia inducible factor alpha in clear cell renal cell carcinoma (2011) (0)
Multiple determinants of antimetabolite action in humans. (1979) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Youcef M. Rustum?

Youcef M. Rustum is affiliated with the following schools:

University of Western Ontario

Youcef M. Rustum's Academic­Influence.com Rankings

Why Is Youcef M. Rustum Influential?

Youcef M. Rustum's Published Works

Published Works

What Schools Are Affiliated With Youcef M. Rustum?

Youcef M. Rustum's AcademicInfluence.com Rankings